Effectiveness of COVID-19 Vaccines in US Military Personnel During Delta Variant | Infectious Diseases | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME
Key Points

Question  Did the effectiveness of the mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 vaccines change among US-based military personnel before and during the predominance of the SARS-CoV-2 Delta (B.1.617.2) variant?

Findings  In this case-control study of 441 379 active US military personnel, overall COVID-19 vaccine effectiveness decreased by 19% from the pre-Delta to the Delta period. JNJ-78436735 had the lowest overall vaccine effectiveness in the pre-Delta (81.8%) and Delta (38.3%) periods.

Meaning  In this study, COVID-19 vaccine effectiveness decreased among US-based military personnel during the time of SARS-CoV-2 Delta variant predominance, especially for recipients of the JNJ-78436735 vaccine; this finding supports the use of booster doses to increase effectiveness.

Abstract

Importance  No studies to date have evaluated the effectiveness of 3 COVID-19 vaccines in the US military population, especially during the circulation of the SARS-CoV-2 Delta (B.1.617.2) variant.

Objective  To estimate the effectiveness of the mRNA-1273, BNT162b2, and JNJ-78436735 vaccines among US military personnel before and during the predominance of the Delta variant in the US.

Design, Setting, and Participants  This case-control study was conducted among all unvaccinated and fully vaccinated US military personnel who had a documented SARS-CoV-2 test performed in the US between January 1 and September 24, 2021. Individuals were identified using Department of Defense (DOD) electronic medical, laboratory, and surveillance databases. The pre-Delta period was defined as January 1 to May 31, 2021, and the Delta period as June 19 to September 24, 2021. Case individuals were defined by a positive polymerase chain reaction SARS-CoV-2 test result or a positive antigen test result with symptoms. Control individuals had at least 1 negative SARS-CoV-2 test result.

Exposures  COVID-19 vaccination with the mRNA-1273, BNT162b2, or JNJ-78436735 vaccine, assessed from DOD electronic vaccination records.

Main Outcomes and Measures  COVID-19 vaccine effectiveness overall, by vaccine type, and by outcome stratified by the pre-Delta and Delta periods in the US. Vaccine effectiveness was estimated as 100 × (1 − odds ratio) in a logistic regression model with adjustment for potential confounders.

Results  The cohort included 441 379 individuals, with 290 256 in the pre-Delta period (236 555 [81%] male; median age, 25 years [range, 17-68 years]) and 151 123 in the Delta period (120 536 [80%] male; median age, 26 years [range, 17-70 years]). Adjusted vaccine effectiveness of all vaccines was significantly higher during the pre-Delta period (89.2%; 95% CI, 88.1%-90.1%) compared with the Delta period (70.2%; 95% CI, 69.3%-71.1%) for all outcomes, an overall decrease of 19%. mRNA-1273 vaccine effectiveness was highest in the pre-Delta (93.5%; 95% CI, 91.9%-94.7%) and Delta (79.4%; 95% CI, 78.3%-80.4%) periods for all outcomes, whereas the JNJ-78436735 vaccine had the lowest effectiveness during the pre-Delta (81.8%; 95% CI, 74.2%- 87.1%) and Delta (38.3%; 95% CI, 34.5%-41.9%) periods. Effectiveness for all vaccines during both periods was higher for symptomatic infection and hospitalization among individuals with SARS-CoV-2 infection.

Conclusions and Relevance  In this case-control study, among US military personnel, COVID-19 vaccine effectiveness was significantly lower during the period when the Delta variant predominated compared with the period before Delta variant predominance; this was especially true for the JNJ-78436735 vaccine. These findings were confounded by time since vaccination; this and the change in effectiveness support the need for booster doses and continued evaluation of vaccine effectiveness as new variants of SARS-CoV-2 emerge.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: March 2, 2022.

Published: April 20, 2022. doi:10.1001/jamanetworkopen.2022.8071

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Eick-Cost AA et al. JAMA Network Open.

Corresponding Author: Angelia A. Eick-Cost, PhD, Armed Forces Health Surveillance Division, Defense Health Agency, 11800 Tech Rd, Ste 220, Silver Spring, MD 20904 (Angelia.a.cost.ctr@mail.mil).

Author Contributions: Drs Eick-Cost and Ying had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Eick-Cost, Wells.

Acquisition, analysis, or interpretation of data: Eick-Cost, Ying.

Drafting of the manuscript: Eick-Cost.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Eick-Cost, Ying.

Administrative, technical, or material support: Eick-Cost, Wells.

Supervision: Wells.

Conflict of Interest Disclosures: None reported.

Additional Contributions: Ms Zheng Hu, MS, Defense Health Agency, Armed Forces Health Surveillance Division, provided biostatistics guidance with the analysis and received no compensation beyond her regular salary.

References
1.
Polack  FP , Thomas  SJ , Kitchin  N ,  et al; C4591001 Clinical Trial Group.  Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine.   N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577 PubMedGoogle ScholarCrossref
2.
Baden  LR , El Sahly  HM , Essink  B ,  et al; COVE Study Group.  Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.   N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389 PubMedGoogle ScholarCrossref
3.
Sadoff  J , Gray  G , Vandebosch  A ,  et al; ENSEMBLE Study Group.  Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19.   N Engl J Med. 2021;384(23):2187-2201. doi:10.1056/NEJMoa2101544 PubMedGoogle ScholarCrossref
4.
Oliver  SE , Gargano  JW , Scobie  H ,  et al.  The Advisory Committee on Immunization Practices’ interim recommendation for use of Janssen COVID-19 vaccine—United States, February 2021.   MMWR Morb Mortal Wkly Rep. 2021;70(9):329-332. doi:10.15585/mmwr.mm7009e4 PubMedGoogle ScholarCrossref
5.
Lopez Bernal  J , Andrews  N , Gower  C ,  et al.  Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant.   N Engl J Med. 2021;385(7):585-594. doi:10.1056/NEJMoa2108891 PubMedGoogle ScholarCrossref
6.
Tartof  SY , Slezak  JM , Fischer  H ,  et al.  Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.   Lancet. 2021;398(10309):1407-1416. doi:10.1016/S0140-6736(21)02183-8 PubMedGoogle ScholarCrossref
7.
Fraley  E , LeMaster  C , Khanal  S ,  et al.  Prior infection and age impacts antibody persistence after SARS-CoV-2 mRNA vaccine.   Clin Infect Dis. Published online September 22, 2021. PubMedGoogle Scholar
8.
Fowlkes  A , Gaglani  M , Groover  K , Thiese  MS , Tyner  H , Ellingson  K ; HEROES-RECOVER Cohorts.  Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (Delta) variant predominance—eight US locations, December 2020–August 2021.   MMWR Morb Mortal Wkly Rep. 2021;70(34):1167-1169. doi:10.15585/mmwr.mm7034e4 PubMedGoogle ScholarCrossref
9.
Glatman-Freedman  A , Bromberg  M , Dichtiar  R , Hershkovitz  Y , Keinan-Boker  L .  The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: a nation-wide retrospective longitudinal multiple cohort analysis using individualised data.   EBioMedicine. 2021;72:103574. doi:10.1016/j.ebiom.2021.103574 PubMedGoogle Scholar
10.
Bruxvoort  KJ , Sy  LS , Qian  L ,  et al.  Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: interim results from a prospective observational cohort study.   Lancet Reg Health Am. 2022;6:100134. doi:10.1016/j.lana.2021.100134PubMedGoogle Scholar
11.
Tenforde  MW , Self  WH , Naioti  EA ,  et al; IVY Network Investigators; IVY Network.  Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adults—United States, March-July 2021.   MMWR Morb Mortal Wkly Rep. 2021;70(34):1156-1162. doi:10.15585/mmwr.mm7034e2 PubMedGoogle ScholarCrossref
12.
Haas  EJ , Angulo  FJ , McLaughlin  JM ,  et al.  Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.   Lancet. 2021;397(10287):1819-1829. doi:10.1016/S0140-6736(21)00947-8 PubMedGoogle ScholarCrossref
13.
Britton  A , Jacobs Slifka  KM , Edens  C ,  et al.  Effectiveness of the Pfizer-BioNTech COVID-19 vaccine among residents of two skilled nursing facilities experiencing COVID-19 outbreaks—Connecticut, December 2020-February 2021.   MMWR Morb Mortal Wkly Rep. 2021;70(11):396-401. doi:10.15585/mmwr.mm7011e3 PubMedGoogle ScholarCrossref
14.
Swift  MD , Breeher  LE , Tande  AJ ,  et al.  Effectiveness of messenger RNA coronavirus disease 2019 (COVID-19) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a cohort of healthcare personnel.   Clin Infect Dis. 2021;73(6):e1376-e1379. doi:10.1093/cid/ciab361 PubMedGoogle ScholarCrossref
15.
Thompson  MG , Stenehjem  E , Grannis  S ,  et al.  Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings.   N Engl J Med. 2021;385(15):1355-1371. doi:10.1056/NEJMoa2110362 PubMedGoogle ScholarCrossref
16.
Thompson  MG , Burgess  JL , Naleway  AL ,  et al.  Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight US locations, December 2020-March 2021.   MMWR Morb Mortal Wkly Rep. 2021;70(13):495-500. doi:10.15585/mmwr.mm7013e3 PubMedGoogle ScholarCrossref
17.
Fabiani  M , Ramigni  M , Gobbetto  V , Mateo-Urdiales  A , Pezzotti  P , Piovesan  C .  Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021.   Euro Surveill. 2021;26(17):2100420. doi:10.2807/1560-7917.ES.2021.26.17.2100420 PubMedGoogle Scholar
18.
Dagan  N , Barda  N , Kepten  E ,  et al.  BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting.   N Engl J Med. 2021;384(15):1412-1423. doi:10.1056/NEJMoa2101765 PubMedGoogle ScholarCrossref
19.
Rosenberg  ES , Dorabawila  V , Easton  D ,  et al.  COVID-19 vaccine effectiveness in New York State.   N Engl J Med. Published online December 1, 2021.PubMedGoogle Scholar
20.
Tada  T , Zhou  H , Samanovic  MI ,  et al.  Comparison of neutralizing antibody titers elicited by mRNA and adenoviral vector vaccine against SARS-CoV-2 variants.   bioRxiv. Preprint posted online August 6, 2021. doi:10.1101/2021.07.19.452771 Google Scholar
21.
Polinski  JM , Weckstein  AR , Batech  M ,  et al.  Effectiveness of the single-dose Ad26.COV2.S COVID vaccine.  medRxiv. Preprint posted online September 16, 2021. doi:10.1101/2021.09.10.21263385
22.
Cohn  BA , Cirillo  PM , Murphy  CC , Krigbaum  NY , Wallace  AW .  SARS-CoV-2 vaccine protection and deaths among US veterans during 2021.   Science. Published online November 4, 2021. doi:10.1126/science.abm0620 PubMedGoogle Scholar
23.
US Department of Defense. DOD announces COVID-19 vaccine distribution plan. December 9, 2020. Accessed February 22, 2022. https://www.defense.gov/News/Releases/Release/article/2440556/dod-announces-covid-19-vaccine-distribution-plan/
24.
Deputy Secretary of Defense. Memorandum: coronavirus disease 2019 vaccine guidance. US Department of Defense. December 7, 2020. Accessed December 9, 2021. https://media.defense.gov/2020/Dec/08/2002548508/-1/-1/0/CORONAVIRUS-DISEASE-2019-VACCINE-GUIDANCE.PDF
25.
US Department of Defense. Under Secretary of Defense memo: force health protection guidance (Supplement 22)—Department of Defense guidance for coronavirus disease 2019 surveillance and screening testing. Accessed February 22, 2022. https://media.defense.gov/2021/Jul/28/2002814137/-1/-1/0/FORCE-HEALTH-PROTECTION-GUIDANCE-SUPPLEMENT-22-DEPARTMENT-OF-DEFENSE-GUIDANCE-FOR-CORONAVIRUS-DISEASE-SURVEILLANCE-AND-SCREEN-TESTING.PDF
26.
Young-Xu  Y , Korves  C , Roberts  J ,  et al.  Coverage and estimated effectiveness of mRNA COVID-19 vaccines among US veterans.   JAMA Netw Open. 2021;4(10):e2128391. doi:10.1001/jamanetworkopen.2021.28391 PubMedGoogle Scholar
27.
Dickerman  BA , Gerlovin  H , Madenci  AL ,  et al.  Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines in US veterans.   N Engl J Med. 2022;386(2):105-115. doi:10.1056/NEJMoa2115463PubMedGoogle ScholarCrossref
28.
Rubertone  MV , Brundage  JF .  The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance.   Am J Public Health. 2002;92(12):1900-1904. doi:10.2105/AJPH.92.12.1900 PubMedGoogle ScholarCrossref
29.
Centers for Disease Control and Prevention. COVID data tracker. Accessed December 9, 2021. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html
30.
Navy Marine Corps Public Health Center. Surveillance and reporting tools. DRSI: disease reporting system internet. Accessed December 9, 2021. https://www.med.navy.mil/Navy-Marine-Corps-Public-Health-Center/Preventive-Medicine/Program-and-Policy-Support/DRSI/
31.
US Census Bureau. Census regions and divisions of the United States. Accessed December 9, 2021. https://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf
32.
Olson  SM , Newhams  MM , Halasa  NB ,  et al; Overcoming COVID-19 Investigators.  Effectiveness of Pfizer-BioNTech mRNA vaccination against COVID-19 hospitalization among persons aged 12-18 years—United States, June-September 2021.   MMWR Morb Mortal Wkly Rep. 2021;70(42):1483-1488. doi:10.15585/mmwr.mm7042e1PubMedGoogle ScholarCrossref
33.
Glatman-Freedman  A , Hershkovitz  Y , Kaufman  Z , Dichtiar  R , Keinan-Boker  L , Bromberg  M .  Effectiveness of BNT162b2 vaccine in adolescents during outbreak of SARS-CoV-2 Delta variant infection, Israel, 2021.   Emerg Infect Dis. 2021;27(11):2919-2922. doi:10.3201/eid2711.211886 PubMedGoogle ScholarCrossref
34.
Reis  BY , Barda  N , Leshchinsky  M ,  et al.  Effectiveness of BNT162b2 vaccine against Delta variant in adolescents.   N Engl J Med. 2021;385(22):2101-2103. doi:10.1056/NEJMc2114290 PubMedGoogle ScholarCrossref
35.
Doria-Rose  N , Suthar  MS , Makowski  M ,  et al; mRNA-1273 Study Group.  Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19.   N Engl J Med. 2021;384(23):2259-2261. doi:10.1056/NEJMc2103916 PubMedGoogle ScholarCrossref
36.
Dan  JM , Mateus  J , Kato  Y ,  et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.   Science. 2021;371(6529):eabf4063. doi:10.1126/science.abf4063 PubMedGoogle Scholar
37.
 Absolute and relative morbidity burdens attributable to various illnesses and injuries, active component, US Armed Forces, 2020.   MSMR. 2021;28(6):2-9.PubMedGoogle Scholar
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close